is the news today - what you already know?
biz.yahoo.com
Anti-Cancer Drug From MGI PHARMA, Inc., Shows Broad-Ranging Activity
Studies Presented at AACR Annual Meeting Demonstrate the MGI 114 Anti-Cancer Compound Inhibits Growth of Human Cancer Cells
MINNEAPOLIS, April 12 /PRNewswire/ -- Researchers at the annual American Association for Cancer Research meeting in Philadelphia, April 10-14, released the results of studies on MGI 114, a cancer-fighting compound derived from a mushroom, showing that the drug has a unique mechanism of action that may be a factor in its ability to inhibit the growth of human cancer cells. MGI 114 is being developed by MGI PHARMA, Inc. (Nasdaq: MOGN - news), and currently is in phase II human clinical trials.
''Early evidence indicates that this drug has the potential to treat a variety of solid tumors, especially those tumors that are resistant to other drugs,'' said Dr. Steve Weitman, a lead investigator of MGI 114 at the Institute for Drug Development, San Antonio, Texas. ''Should MGI 114 prove to be as effective in humans as it has been in animal studies, it could one day touch the lives of the many thousands of Americans diagnosed with cancer each year.''
|
